{"id":"https://openalex.org/W2955280685","doi":"https://doi.org/10.1158/1538-7445.am2019-363","title":"Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors","display_name":"Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W2955280685","doi":"https://doi.org/10.1158/1538-7445.am2019-363","mag":"2955280685"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-363","doi":"https://doi.org/10.1158/1538-7445.am2019-363","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-363","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016645669","display_name":"Tyler M. Maclay","orcid":"https://orcid.org/0000-0001-5373-7266","observed_orcids":["https://orcid.org/0000-0001-5373-7266"]},"institutions":[{"id":"https://openalex.org/I4210132953","display_name":"Cyteir Therapeutics (United States)","ror":"https://ror.org/042228s94","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132953"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tyler Maclay","raw_affiliation_strings":["Cyteir Therapeutics, Lexington, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cyteir Therapeutics, Lexington, MA","institution_ids":["https://openalex.org/I4210132953"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083416148","display_name":"Melinda A. L. Day","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132953","display_name":"Cyteir Therapeutics (United States)","ror":"https://ror.org/042228s94","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132953"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melinda Day","raw_affiliation_strings":["Cyteir Therapeutics, Lexington, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cyteir Therapeutics, Lexington, MA","institution_ids":["https://openalex.org/I4210132953"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5020676516","display_name":"Kevin D. Mills","orcid":"https://orcid.org/0009-0000-7805-1420","observed_orcids":["https://orcid.org/0009-0000-7805-1420"]},"institutions":[{"id":"https://openalex.org/I4210132953","display_name":"Cyteir Therapeutics (United States)","ror":"https://ror.org/042228s94","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132953"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Mills","raw_affiliation_strings":["Cyteir Therapeutics, Lexington, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cyteir Therapeutics, Lexington, MA","institution_ids":["https://openalex.org/I4210132953"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210132953"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"363","last_page":"363"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.0215000007301569,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rad51-inhibitors","display_name":"RAD51 inhibitors","score":0.984000027179718},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9789999723434448},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.7850000262260437},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.9330000281333923},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.8080000281333923},{"id":"https://openalex.org/keywords/parp-inhibitor-resistance","display_name":"PARP inhibitor resistance","score":0.6859999895095825},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.46000000834465027},{"id":"https://openalex.org/keywords/genomic-instability","display_name":"genomic instability","score":0.6769999861717224},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9309999942779541},{"id":"https://openalex.org/keywords/head-and-neck-cancer","display_name":"head and neck cancer","score":0.7720000147819519},{"id":"https://openalex.org/keywords/activation-induced-cytidine-deaminase","display_name":"activation-induced cytidine deaminase","score":0.7440000176429749},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5139999985694885},{"id":"https://openalex.org/keywords/loewe-additivity","display_name":"Loewe additivity","score":0.6309999823570251},{"id":"https://openalex.org/keywords/bliss-independence","display_name":"Bliss independence","score":0.9629999995231628},{"id":"https://openalex.org/keywords/cancer-cell-lines","display_name":"cancer cell lines","score":0.49799999594688416}],"concepts":[{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.8589050769805908},{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.7361235618591309},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6626836657524109},{"id":"https://openalex.org/C2778502085","wikidata":"https://www.wikidata.org/wiki/Q7662767","display_name":"Synthetic lethality","level":4,"score":0.5904307961463928},{"id":"https://openalex.org/C2781312401","wikidata":"https://www.wikidata.org/wiki/Q7919041","display_name":"Veliparib","level":5,"score":0.5785365104675293},{"id":"https://openalex.org/C2779012473","wikidata":"https://www.wikidata.org/wiki/Q3235015","display_name":"RAD51","level":4,"score":0.5765503644943237},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.5669204592704773},{"id":"https://openalex.org/C178169997","wikidata":"https://www.wikidata.org/wiki/Q2892636","display_name":"Genome instability","level":4,"score":0.5509119629859924},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.5411597490310669},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.5357678532600403},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.5100115537643433},{"id":"https://openalex.org/C2776985229","wikidata":"https://www.wikidata.org/wiki/Q18021211","display_name":"Cytidine deaminase","level":3,"score":0.47737380862236023},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4264797568321228},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38711661100387573},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3481268584728241},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.2326917052268982},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12837398052215576},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0952591598033905},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.07188770174980164}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-363","doi":"https://doi.org/10.1158/1538-7445.am2019-363","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-363","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2915287167","https://openalex.org/W3007772657","https://openalex.org/W2953858362","https://openalex.org/W2885971707","https://openalex.org/W2996452612","https://openalex.org/W2036180332","https://openalex.org/W2765752112","https://openalex.org/W7095816770","https://openalex.org/W2984934173","https://openalex.org/W2151876400"],"abstract_inverted_index":{"Abstract":[0],"Genomic":[1],"instability":[2,28],"is":[3,136,313,351],"recognized":[4],"as":[5,123,339],"a":[6,50,124,156,340,380],"driver":[7],"of":[8,14,19,82,102,139,165,204,286,320,392],"tumorigenesis":[9],"and":[10,29,72,97,169,191,208,220,232,242,357,365],"cancer":[11,222,362],"progression.":[12],"Loss":[13],"tumor":[15,75,266],"suppressors":[16],"or":[17,253],"activation":[18],"oncogenes":[20],"can":[21,39],"induce":[22,44],"DNA":[23,34,83,87],"damage":[24,84],"stress,":[25],"promoting":[26],"genomic":[27],"creating":[30],"dependencies":[31,38],"upon":[32],"key":[33],"repair":[35,88],"pathways.":[36],"These":[37,331],"be":[40,61,337],"targeted":[41],"therapeutically":[42],"to":[43,60,117,126,133,167,177,181,185,189,194,247,315],"synthetic":[45],"lethality.":[46],"We":[47,104,235],"have":[48,57,105,115],"developed":[49],"novel":[51,381],"RAD51":[52,94,120,149,356,382],"inhibitor,":[53,383],"CYT01B,":[54,379],"which":[55],"we":[56,257,305,347],"previously":[58],"shown":[59],"preferentially":[62],"active":[63,338],"in":[64,73,111,201,264,280,360,369],"Activation":[65],"Induced":[66],"Cytidine":[67],"Deaminase":[68],"(AID)":[69],"expressing":[70],"cells,":[71],"other":[74],"derived":[76,267],"cell":[77,202,216,223,228,268,274],"lines":[78,203],"with":[79,109,161,260,295,311,343,386],"elevated":[80],"levels":[81],"and/or":[85],"reduced":[86],"capabilities.":[89],"CYT01B":[90,110,162,312,335],"acts":[91,384],"by":[92],"reducing":[93],"focus":[95],"formation,":[96],"depleting":[98],"the":[99,137,238,243,262,265,271,281,287,292,298,308,316,321,327,329,393],"nuclear":[100],"pool":[101],"RAD51.":[103],"observed":[106,258,278],"anti-tumor":[107],"effects":[108],"preclinical":[112],"models,":[113],"but":[114],"yet":[116],"determine":[118,152,248],"if":[119],"could":[121],"act":[122],"sensitizer":[125],"current":[127],"therapeutics.":[128],"A":[129],"main":[130],"resistance":[131],"mechanism":[132],"PARP":[134,172,209,293,317,322,344,358,387],"inhibitors":[135,173,388],"overexpression":[138],"RAD51,":[140],"making":[141],"it":[142],"an":[143],"attractive":[144],"potential":[145,153,353],"combination":[146,197],"for":[147,354,396],"our":[148],"inhibitor.":[150],"To":[151],"drug":[154,249],"synergy,":[155],"matrix":[157,198],"study":[158],"was":[159,199,277],"performed":[160],"(concentration":[163],"range":[164],"20nM":[166],"5\u00b5M)":[168],"5":[170],"different":[171],"including":[174],"olaparib":[175,282,296],"(78nM":[176,180],"5\u00b5M),":[178,182],"niraparib":[179],"veliparib":[183],"(780nM":[184],"50\u00b5M),":[186],"rucaparib":[187],"(156nM":[188],"10\u00b5M),":[190],"talazoparib":[192],"(39nM":[193],"2.5\u00b5M).":[195],"The":[196,284],"tested":[200],"varying":[205],"AID":[206],"expression":[207],"inhibitor":[210],"sensitivity:":[211],"ARPE19/HPV16":[212],"(HPV":[213],"immortalized":[214],"epithelial":[215,273],"line),":[217,224,229],"KYSE-70":[218],"(head":[219],"neck":[221],"Daudi":[225],"(Burkitt\u2019s":[226],"Lymphoma":[227],"HCC1143":[230],"(TNBC),":[231],"BT20":[233],"(TNBC).":[234],"used":[236],"both":[237],"Loewe":[239],"Additivity":[240],"model":[241,246],"Bliss":[244],"Independence":[245],"interaction":[250],"(synergistic,":[251],"independent,":[252],"antagonistic).":[254],"In":[255,270],"general,":[256],"synergy":[259,276,300],"all":[261],"combinations":[263],"lines.":[269],"transformed":[272],"line,":[275],"only":[279],"combination.":[283],"strength":[285],"synergistic":[288,309],"effect":[289],"differed":[290],"amongst":[291],"inhibitors,":[294],"giving":[297],"strongest":[299],"scores.":[301],"From":[302],"this":[303],"data":[304,332],"hypothesize":[306],"that":[307,334,349],"activity":[310],"related":[314],"trapping":[318,325],"efficiency":[319,326],"inhibitors;":[323],"greater":[324,328],"synergy.":[330],"suggest":[333],"may":[336],"combinatorial":[341],"therapy":[342],"inhibitors.":[345],"Overall,":[346],"conclude":[348],"there":[350],"significant":[352],"combining":[355],"inhibition":[359],"future":[361,367],"treatment":[363],"strategies,":[364],"warrants":[366],"exploration":[368],"vivo.":[370],"Citation":[371],"Format:":[372],"Tyler":[373],"Maclay,":[374],"Melinda":[375],"Day,":[376],"Kevin":[377],"Mills.":[378],"synergistically":[385],"[abstract].":[389],"In:":[390],"Proceedings":[391],"American":[394],"Association":[395],"Cancer":[397,411],"Research":[398],"Annual":[399],"Meeting":[400],"2019;":[401],"2019":[402],"Mar":[403],"29-Apr":[404],"3;":[405],"Atlanta,":[406],"GA.":[407],"Philadelphia":[408],"(PA):":[409],"AACR;":[410],"Res":[412],"2019;79(13":[413],"Suppl):Abstract":[414],"nr":[415],"363.":[416]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2019-07-12T00:00:00"}